🟠 Moderate Evidence
New surveillance data from the UK Health Security Agency reveals evolving patterns in healthcare-associated infections across English hospitals, with antimicrobial-resistant organisms continuing to pose significant challenges to patient safety. The monthly surveillance report, published as part of the UK’s mandatory reporting system, tracks MRSA, MSSA, Gram-negative bacteraemia, and Clostridioides difficile infections by healthcare organisation and infection onset location.
Key takeaways
- Government surveillance tracks four major healthcare-associated infection types across English hospitals
- Data includes organisation-specific infection rates and location of onset analysis
- Clostridioides difficile monitoring includes prior healthcare exposure tracking
Healthcare-Associated Infections Under UK Surveillance
Mandatory reporting pathogens, by infection type
Source: UK Health Security Agency, 2025-2026 | Georgian Medical Journal News
Mandatory Surveillance System Tracks Key Pathogens
The UK’s healthcare-associated infection surveillance programme requires all NHS acute trusts to report specific infection types, enabling real-time tracking of antimicrobial resistance trends and healthcare-associated transmission patterns according to the UK Health Security Agency.
MRSA and MSSA bacteraemia cases are classified by onset location, distinguishing between community-acquired infections and those developing during hospitalisation. Healthcare organisations must report both the total number of infections and their distribution across different clinical areas, enabling identification of high-risk departments and patient populations according to the UK Health Security Agency surveillance programme.
Gram-negative Bacteria Surveillance Expands
The surveillance programme includes comprehensive monitoring of Gram-negative bacteraemia, encompassing Escherichia coli, Klebsiella species, and Pseudomonas aeruginosa infections. The data supports targeted infection control measures and informs national quality and safety initiatives.
Clostridioides Difficile Monitoring Includes Exposure History
The C. difficile surveillance component tracks prior healthcare exposure, recognising that many infections develop following antibiotic treatment in healthcare settings according to the UK Health Security Agency reporting system. Prior trust exposure data enables healthcare organisations to identify potential transmission sources and implement targeted prevention strategies.
The system supports both individual organisation quality improvement efforts and national policy development, contributing to broader health policy initiatives addressing antimicrobial resistance.
The mandatory surveillance system enables organisation-specific infection rate analysis and supports targeted intervention strategies across English healthcare trusts.
— UK Health Security Agency, Healthcare-Associated Infection Surveillance Programme (2025)
What this means
Frequently asked questions
Why are these specific pathogens monitored?
MRSA, MSSA, Gram-negative bacteria, and C. difficile are tracked as part of the UK’s mandatory healthcare-associated infection surveillance system operated by the UK Health Security Agency.
How does location of onset classification work?
The UK Health Security Agency surveillance system classifies infections by onset location, distinguishing between community-acquired infections and those developing during hospitalisation.
What happens to surveillance data after collection?
According to the UK Health Security Agency, data undergoes quality assurance processes before publication and feeds into national antimicrobial resistance monitoring programmes. Individual organisation reports support local quality improvement while aggregate data informs national policy development.
The UK Health Security Agency surveillance programme continues to monitor healthcare-associated infections across English hospitals, with data collection serving both local quality improvement and national strategy development objectives.
Source: MRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
